FDA pulls J&J's Invokana boxed warning after reviewing amputation risks—but the sales damage is done

Sales of Johnson & Johnson’s diabetes drug Invokana have suffered since the FDA slapped a boxed warning on its label detailing the product’s amputation risks. But in an about-face, the agency now says it’s removed that warning.